Pipeline
More than game changing.
Life changing.
The surest path to clinical, regulatory, and commercial success starts with validated biology. That’s why we’re focused on acquiring and developing product candidates that possess a clear mechanism of action and that aim to address diseases with well-understood pathophysiology and significant unmet medical need. We believe that targeting the causal biology of a disease provides the highest probability of dramatically improving the lives of patients.
With this approach, we’re building a broad and sustainable pipeline of product candidates with the potential to change the odds for patients with rare diseases in the areas of hematology, immuno-inflammation, maternal fetal health, ophthalmology, and metabolic disorders.
Rapidly Advancing Our Diversified Portfolio
Therapeutic Area | Programs | Molecule | Approach | Discovery | Preclinical | Phase 1 | Phase 2 | Phase 3 | Development Rights |
---|---|---|---|---|---|---|---|---|---|
Maternal Fetal Blood Disorders | Prevention of FNAIT | RLYB212 | Anti-HPA-1a Monoclonal Antibody | ||||||
Complement Dysregulation | Rare Diseases | RLYB116 | C5 Inhibitor; Affibody-ABD Fusion | ||||||
Ophthalmology | RLYB114 | C5 Inhibitor; Pegylated Affibody | |||||||
Hematology | Severe Anemia | RLYB331 | Matriptase-2 Inhibitor; Monoclonal Antibody | ||||||
Metabolic Disorders | HPP | ENPP1 program | ENPP1 Small Molecule Inhibitor | ||||||
Undisclosed | Undisclosed | Undisclosed | |||||||
FNAIT: Fetal and neonatal alloimmune thrombocytopenia; HPA-1a: Human platelet antigen 1a; ABD: Albumin binding domain; HPP: Hypophosphatasia; ENPP1: Ectonucleotide pyrophosphatase/phosphodiesterase 1 |
Partnerships
Finding treatments for rare disease isn’t about us. It’s about all of us.
There are thousands of rare diseases that have no effective treatment options. That’s why we’re actively working to accelerate innovation by all means possible — including acquiring and in-licensing promising product candidates and expanding our partnerships.
We’ve assembled a team with a track record of developing and commercializing therapies for patients with rare diseases. Our success has made us a partner of choice with leaders in industry and in academic clinical centers worldwide. We continue to collaborate with these experts to further our business development opportunities and expand our portfolio.
If you’re looking to accelerate the development of a product candidate that is aligned with Rallybio’s mission, please contact us at [email protected].